Oryzon Getting $300,000 to Continue Developing Alzheimer’s Therapy ORY-2001

Oryzon Getting $300,000 to Continue Developing Alzheimer’s Therapy ORY-2001
Oryzon Genomics is receiving $300,000 from the Alzheimer’s Drug Discovery Foundation to continue developing its Alzheimer’s treatment ORY-2001. In exchange, the foundation, which has been a longtime partner of Oryzon, will receive shares of the company’s stock. Oryzon develops epigenetics therapies, which regulate genome function without affecting the makeup of genes themselves. “Regulation of gene transcription has emerged as a

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *